The Nifty Healthcare Index has just delivered a high-conviction structural breakout on the daily timeframe. After consolidating for nearly 18 months below a major supply zone, the index has decisively cleared its previous peak, signaling the start of a potential multi-quarter bullish cycle for the healthcare sector.
Key Technical Observations:
Major Horizontal Breakout: The index has successfully surged past the critical resistance level at 15,072. This level has acted as a formidable ceiling since late 2024; flipping this into support is a massive bullish milestone.
All-Time High (ATH) Momentum: By trading at record levels, the index is now in "Blue Sky Territory." Without any historical overhead supply to act as resistance, the momentum is expected to accelerate as price discovery takes over.
Exponential Moving Average Support: The price is trending well above its 20, 50, and 100-day EMAs. The shorter-term EMAs are beginning to fan out and slope upwards, providing a strong dynamic cushion for the current rally.
Long-Term Base Completion: The massive rounding structure/base formed over the last year and a half suggests that a significant amount of accumulation has taken place, which could lead to a powerful and sustained upward move.
Technical Setup:
Entry: Current Market Price (15,072) or on a successful retest of the breakout zone between 14,800 - 15,000.
Stop Loss (SL): 14,200 (Placed safely below the recent swing low and the 50-day EMA support).
Targets:
Target 1: 16,500 (Immediate psychological and momentum target)
Target 2: 18,200+ (Based on the measured move of the 18-month consolidation base)
Disclaimer:
This analysis is for educational and informational purposes only. Trading in financial indices involves significant risk. Please conduct your own research or consult with a SEBI-registered financial advisor before making any investment decisions. I am not a SEBI-registered advisor.
This sector breakout is structurally very strong—are you looking to trade the index directly or using this to filter for high-momentum pharma and healthcare stocks?
Key Technical Observations:
Major Horizontal Breakout: The index has successfully surged past the critical resistance level at 15,072. This level has acted as a formidable ceiling since late 2024; flipping this into support is a massive bullish milestone.
All-Time High (ATH) Momentum: By trading at record levels, the index is now in "Blue Sky Territory." Without any historical overhead supply to act as resistance, the momentum is expected to accelerate as price discovery takes over.
Exponential Moving Average Support: The price is trending well above its 20, 50, and 100-day EMAs. The shorter-term EMAs are beginning to fan out and slope upwards, providing a strong dynamic cushion for the current rally.
Long-Term Base Completion: The massive rounding structure/base formed over the last year and a half suggests that a significant amount of accumulation has taken place, which could lead to a powerful and sustained upward move.
Technical Setup:
Entry: Current Market Price (15,072) or on a successful retest of the breakout zone between 14,800 - 15,000.
Stop Loss (SL): 14,200 (Placed safely below the recent swing low and the 50-day EMA support).
Targets:
Target 1: 16,500 (Immediate psychological and momentum target)
Target 2: 18,200+ (Based on the measured move of the 18-month consolidation base)
Disclaimer:
This analysis is for educational and informational purposes only. Trading in financial indices involves significant risk. Please conduct your own research or consult with a SEBI-registered financial advisor before making any investment decisions. I am not a SEBI-registered advisor.
This sector breakout is structurally very strong—are you looking to trade the index directly or using this to filter for high-momentum pharma and healthcare stocks?
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.